Global pharma powerhouse Vertex Pharmaceuticals has announced that its experimental kidney disease therapy, povetacicept, delivered striking results in a pre-specified Week 36 interim analysis of the Phase 3 RAINIER trial for immunoglobulin A nephropathy (IgAN).

 

The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in urine protein to creatinine ratio (UPCR) at Week 36. This translated into a statistically significant 49.8% reduction compared to placebo, consistent across all pre-specified patient subgroups.

 

Secondary endpoints also showed robust benefits. Povetacicept patients experienced a 77.4% drop in serum galactose deficient IgA1 (Gd-IgA1) versus a 9.1% increase in placebo, a 79.3% difference. Among patients with baseline hematuria, 85.1% achieved hematuria resolution on povetacicept, compared with 23.4% on placebo.

 

Safety data were encouraging. Povetacicept was generally well tolerated, with most adverse events mild to moderate. No deaths or serious adverse events were linked to the drug, and there were no opportunistic infections or treatment discontinuations due to infection.

 

“The Phase 3 RAINIER 36-week interim analysis results in IgAN are remarkable. With its clinical profile, dosing and administration advantage, and breadth of potential indications, povetacicept demonstrates best-in-class potential and establishes renal medicine as Vertex’s fourth franchise alongside cystic fibrosis, hematology and acute pain,” said Reshma Kewalramani, Chief Executive Officer and President of Vertex.

 

“As a nephrologist, I am struck by the rapid, deep and sustained response to povetacicept, as well as the consistency of benefit across all subgroups. These results are important for patients with IgAN and also bring us one step closer to realizing povetacicept’s pipeline-in-a-product promise. We thank the patients and trial investigators for their trust and for making RAINIER the largest and fastest enrolling of any contemporary IgAN trial.”

 

RAINIER is a global, randomized, double-blind, placebo-controlled Phase 3 trial testing povetacicept 80 mg subcutaneously every four weeks in patients on standard-of-care therapy. The study enrolled 605 patients, with 199 included in the interim analysis population.